QL1706 Plus Anlotinib for Advanced Lung Cancer After Prior Treatments
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (QL1706 and anlotinib) for patients whose advanced lung cancer has progressed despite prior chemotherapy and immunotherapy. The goal is to see if this combination can help control the cancer when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–80 years old
- You have been diagnosed with small cell lung cancer or lung squamous cell carcinoma (confirmed by tissue sample)
- You have received 2–3 prior treatment lines, including platinum-based chemotherapy and PD-1/PD-L1 immunotherapy
- Your cancer has measurable tumors visible on a CT scan
- You are in good enough health to tolerate treatment (ECOG performance status 0–1, meaning you can do light or normal activities)
- Your blood counts, kidney, and liver function are adequate enough for the study drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of radiation therapy and a targeted drug (Anlotinib) for people with a type of advanced lung cancer that cannot be treated with standard chemoradiation. It may help if your cancer has not spread to other parts of the body and you have not had certain prior treatments.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy and a type of high-dose radiation therapy called Quad Shot for people with advanced lung cancer that has no known gene mutations. The goal is to see if this combination helps shrink tumors and improve outcomes.
This study tests whether adding a combination of immunotherapy (TQB2450) and an anti-angiogenic drug (anlotinib) after standard chemoradiation helps keep limited-stage small cell lung cancer from coming back. It is for people who have just finished chemoradiation and whose cancer did not progress.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.